This company listing is no longer active
IBEX Technologies (IBT) Stock Overview
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IBT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
IBEX Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.44 |
| 52 Week High | CA$1.45 |
| 52 Week Low | CA$0.75 |
| Beta | -0.045 |
| 1 Month Change | 1.41% |
| 3 Month Change | 30.91% |
| 1 Year Change | 73.49% |
| 3 Year Change | 300.00% |
| 5 Year Change | 772.73% |
| Change since IPO | -66.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBT | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | -14.1% | -1.2% |
| 1Y | 73.5% | 3.5% | 31.4% |
Return vs Industry: IBT exceeded the Canadian Biotechs industry which returned -29.5% over the past year.
Return vs Market: IBT exceeded the Canadian Market which returned 7.8% over the past year.
Price Volatility
| IBT volatility | |
|---|---|
| IBT Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 10.1% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 3.8% |
Stable Share Price: IBT's share price has been volatile over the past 3 months.
Volatility Over Time: IBT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | n/a | Paul Baehr | www.ibex.ca |
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research.
IBEX Technologies Inc. Fundamentals Summary
| IBT fundamental statistics | |
|---|---|
| Market cap | CA$35.30m |
| Earnings (TTM) | CA$3.98m |
| Revenue (TTM) | CA$8.00m |
Is IBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBT income statement (TTM) | |
|---|---|
| Revenue | CA$8.00m |
| Cost of Revenue | CA$2.23m |
| Gross Profit | CA$5.77m |
| Other Expenses | CA$1.79m |
| Earnings | CA$3.98m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 72.11% |
| Net Profit Margin | 49.70% |
| Debt/Equity Ratio | 0% |
How did IBT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/04/08 13:14 |
| End of Day Share Price | 2024/04/08 00:00 |
| Earnings | 2024/01/31 |
| Annual Earnings | 2023/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IBEX Technologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.